You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment
  1. E E Gabison1,2,
  2. A Labbé2,3,
  3. F Brignole-Baudouin2,
  4. H Nourry4,
  5. M Putterman1,
  6. F Malecaze5,
  7. T Hoang-Xuan1,
  8. C Baudouin2,3
  1. 1
    Department of Ophthalmology at Fondation Ophtalmologique A. de Rothschild and Bichat Hospital, Paris, APHP, France
  2. 2
    INSERM U598, University Paris 5, France
  3. 3
    Department of Ophthalmology III at Centre Hospitalier National d’Ophtalmologie des XV–XX, Ambroise Paré Hospital, APHP, University of Versailles, Versailles, France
  4. 4
    Pharmacy Department, Centre Hospitalier National d’Ophtalmologie des XV–XX, Paris, France
  5. 5
    Ophthalmology Department, Purpan Hospital, Toulouse, France
  1. Correspondence to Dr E Gabison, Hôpital Bichat, APHP and Fondation Ophtalmologique A. de Rothschild, 25–29 rue Manin, 75940 Paris Cedex 19, France; egabison{at}free.fr

https://doi.org/10.1136/bjo.2008.143859

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Recombinant interferon alpha (IFN2B) is a proposed therapy for corneal intraepithelial neoplasia (CIN). Clinical response to this treatment is frequently challenging due to the delay between initiation of the IFN2B topical application and the beginning of CCIN regression. We present the case of a successful IFN2B treatment with prospective in vivo confocal microscopy imaging.

    Case report

    A 50-year-old man was referred to our department for a recurrence of a conjunctival–corneal intraepithelial neoplasia (CCIN) in his right eye. A 2-month course of topical 0.02% mitomycin C (MMC) therapy was withdrawn a month earlier due to lid allergy. The lesion extended nasally from conjunctiva to peripheral cornea. Despite a surgical excision with cryotherapy, the intraepithelial neoplasia recurred 1 month later in the peripheral cornea (figs 1, 2). Since the large limbal resection and MMC treatment presented the risk of corneal epithelial stem cell deficiency, IFN2B was chosen as a subsequent therapeutic procedure.1 The follow-up included slit lamp and in vivo confocal microscopy examination on a monthly basis during 6 months. Under this regimen, healing was observed within …

    View Full Text

    Footnotes

    • Competing interests None.

    • Ethics approval Ethics approval was provided by Paris University (XV–XX).

    • Patient consent Obtained.

    • Provenance and Peer review Not commissioned; externally peer reviewed.